SCHEMBL1813853

SCHEMBL1813853

FC(F)(F)c1cccc(Oc2cc(Br)cc(Br)c2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEAD1 P28347 2/20 0.51
L3MBTL1 Q9Y468 4/20 0.47
NPSR1 Q6W5P4 3/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
ATM Q13315 1/20 0.46
LTA4H P09960 1/20 0.46
KIF11 P52732 1/20 0.46
ALDH1A1 P00352 2/20 0.44
POLB P06746 2/20 0.44
MAPT P10636 2/20 0.43
TLR8 Q9NR97 1/20 0.43
ABCG2 Q9UNQ0 1/20 0.43
EPAS1 Q99814 1/20 0.42
ADORA2A P29274 1/20 0.42
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9546439 0.91 NPSR1 (0.53) TEAD1L3MBTL1NPSR1CYP1A2CYP2C9
SCHEMBL29603301 0.91 NPSR1 (0.53) TEAD1L3MBTL1NPSR1CYP1A2CYP2C9
SCHEMBL9798371 0.87 LTA4H (0.54) TEAD1L3MBTL1NPSR1CYP1A2CYP2C9
SCHEMBL3553556 0.86 LTA4H (0.52) TEAD1L3MBTL1NPSR1CYP1A2CYP2C9
SCHEMBL27579381 0.83 LTA4H (0.59) TEAD1L3MBTL1NPSR1CYP1A2CYP2C9
SCHEMBL28909069 0.82 TLR8 (0.48) TEAD1L3MBTL1NPSR1CYP1A2CYP2C9
SCHEMBL9546526 0.81 L3MBTL1 (0.55) TEAD1L3MBTL1NPSR1CYP1A2CYP2C9
SCHEMBL21820019 0.80 SMN1; SMN2 (0.48) LTA4HALDH1A1MAPTABCG2TSHR
SCHEMBL1417678 0.79 THRA (0.52) TEAD1L3MBTL1NPSR1CYP1A2CYP2C9
SCHEMBL4453344 0.79 LMNA (0.54) TEAD1L3MBTL1NPSR1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426473-B2 Phenoxy acetic acids as PPAR delta activators High Point Pharnaceuticals, LLC (US) 2013-04-23 US disclosed
US-20120232080-A1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-09-13 US disclosed
US-8217086-B2 Phenoxy acetic acids as PPAR delta activators HIGH POINT PHARMACEUTICALS, LLC (US) 2012-07-10 US disclosed
EP-1899302-B1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS HIGH POINT PHARMACEUTICALS LLC (US) 2011-10-19 EP disclosed
US-20110183982-A1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS HIGH POINT PHARMACEUTICALS, LLC (US) 2011-07-28 US disclosed
US-7943669-B2 Phenoxy acetic acids as PPAR delta activators HIGH POINT PHARMACEUTICALS, LLC (US) 2011-05-17 US disclosed
US-20090192162-A1 Phenoxy Acetic Acids as PPAR Delta Activators TRANSTECH PHARMA, INC. (NC) 2009-07-30 US disclosed
EP-1899302-A1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS Novo Nordisk A/S (DK) 2008-03-19 EP disclosed
WO-2007003581-A1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS NOVO NORDISK A/S (DK) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192162-A1 Phenoxy Acetic Acids as PPAR Delta Activators PPARA, PPARG, PPARD TEAD1 818/4885L3MBTL1 4834/4885NPSR1 1795/4885
US-20120232080-A1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS PPARA, PPARG, PPARD TEAD1 818/4885L3MBTL1 4834/4885NPSR1 1795/4885
US-20110183982-A1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS PPARA, PPARG, PPARD TEAD1 818/4885L3MBTL1 4834/4885NPSR1 1795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.